| http://www.w3.org/ns/prov#value | - While otelixizumab did show success at higher levels, increasing beta-cell function by as much as 80 percent after 30 months, according to researchers at the Belgian Diabetes Registry, side effects including the reactivation of latent Epstein-Barr virus ??? a member of the herpes family associated with mononucleosis and a host of other immune disorders ??? led to the study of lower doses of the dr
|
